Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040360 · ClinicalTrials.gov registry record · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
A Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT05040360 is a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 141 participants, above the 81-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05040360, a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Temozolomide
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Tower Cancer Research Foundation - Beverly Hills
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05040360
The ClinicalTrials.gov registry entry for NCT05040360 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (74% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Malignant Neoplasm in the Liver appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT05040360 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05040360 about?
NCT05040360 is a clinical study titled "Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors". This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either ...
What is the current status of trial NCT05040360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2022-05-05. Estimated completion is 2027-03-31.
What conditions does trial NCT05040360 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8.
What interventions are being tested in trial NCT05040360?
The interventions under investigation include: Capecitabine (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT05040360?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040360 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
RECRUITING · Phase 2
-
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
RECRUITING · NA
Explore more on PlainTrial
Metastatic Malignant Neoplasm in the Liver
All registered trials for this condition
Pancreatic Neuroendocrine Tumor
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.